KELOWNA, British Columbia, June 14, 2017 /PRNewswire/ --
Marapharm Ventures Inc. (OTCQB: MRPHF) (CSE: MDM.CN) (FSE:2MO) ("Marapharm" or the " Company") (http://www.marapharm.com/), Board of Directors has appointed Brian Lovig as Interim-President while the Company expands its operations and prepares to scale production in
Brian Lovig is a businessman with vast entrepreneurial experience who has been involved in the establishment of multiple businesses in multiple sectors. He is the founder and facilitator of Marapharm and from time to time has been a consultant to Marapharm and is familiar with its current projects and personnel.
"Marapharm recently was issued Medical Marijuana Licenses for 290,000 square feet of cultivation and production in the state of Nevada. It is expected that these will transition to recreational licenses. Marapharm is growing rapidly in other states also and has asked for my help with operations, so I've agreed to a six month work plan. I have arranged for others to manage most of my other businesses so that I am able to focus on Marapharm. I've consulted for Marapharm and have brought opportunities to Marapharm in the past which have had a lot of value added by the Marapharm team for shareholders. I'm looking forward to doing some big things during the short time that I will be at the helm." - Brian Lovig, Marapharm President.
ABOUT MARAPHARM VENTURES INC.
Marapharm has more than 300,000 square feet of medical marijuana licenses for its land and facilities in WA, CA and NV. In Nevada, the building footprint is 360,000 square feet. The Nevada Department of Agriculture report by Tessa Rognier states that the average size of a cultivation facility in Nevada is 26,000 square feet. About three years ago, Marapharm applied in Canada to Health Canada for a MMPR (production and sales) license and has passed the necessary security clearances. The application is currently in the in-depth screening process. In September 2016, Health Canada contacted Marapharm with a provision to amend its application to allow for the new regulations, ACMPR. Marapharm owns 15 million shares and warrants of Veritas Pharma Inc., a public company.
Additional information on the operations or financial results of Marapharm are included in reports on file with applicable securities regulatory authorities and may be accessed through the CSE website (http://www.thecse.com), the OTC website (http://www.otcmarkets.com), and the SEDAR website (http://www.sedar.com) under the profile for Marapharm Ventures Inc.
Marapharm trades in Canada, ticker symbol MDM on the CSE, in the United States, ticker symbol MRPHF on the OTCQB, in Europe, ticker symbol 2M0 on the FSE.
Neither the CSE, the FSE nor the OTCQB® has approved nor disapproved the contents of this press release. Neither the CSE, the FSE nor the OTCQB® accepts responsibility for the adequacy or accuracy of this release.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute forward looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", 'may", "will", "project", "should", 'believe", and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements are based on reasonable assumption but no assurance can be given that these expectations will prove to be correct and the forward-looking statements included in this news release should not be unduly relied upon.
FOR FURTHER INFORMATION: http://www.marapharm.com or +1-778-583-4476, email firstname.lastname@example.org
SOURCE Marapharm Ventures Inc.
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All